ESSA Pharma Stock Forecast, Price & News

+0.45 (+1.68 %)
(As of 06/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume69,482 shs
Average Volume318,930 shs
Market Capitalization$921.86 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

ESSA Pharma logo

About ESSA Pharma

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.45 out of 5 stars

Medical Sector

659th out of 2,102 stocks

Pharmaceutical Preparations Industry

322nd out of 832 stocks

Analyst Opinion: 2.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ESSA Pharma (NASDAQ:EPIX) Frequently Asked Questions

Is ESSA Pharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ESSA Pharma stock.
View analyst ratings for ESSA Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than ESSA Pharma?

Wall Street analysts have given ESSA Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ESSA Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ESSA Pharma's next earnings date?

ESSA Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for ESSA Pharma

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) posted its earnings results on Thursday, May, 6th. The company reported ($0.36) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.15.
View ESSA Pharma's earnings history

How has ESSA Pharma's stock price been impacted by COVID-19 (Coronavirus)?

ESSA Pharma's stock was trading at $4.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EPIX shares have increased by 570.5% and is now trading at $27.29.
View which stocks have been most impacted by COVID-19

What price target have analysts set for EPIX?

5 equities research analysts have issued 12-month price objectives for ESSA Pharma's shares. Their forecasts range from $17.00 to $50.00. On average, they anticipate ESSA Pharma's stock price to reach $33.75 in the next year. This suggests a possible upside of 23.7% from the stock's current price.
View analysts' price targets for ESSA Pharma
or view top-rated stocks among Wall Street analysts.

Who are ESSA Pharma's key executives?

ESSA Pharma's management team includes the following people:
  • Dr. David Ross Parkinson, Pres, CEO & Director (Age 71, Pay $788.6k)
  • Mr. Peter A. Virsik M.B.A., M.S., Exec. VP & COO (Age 50, Pay $615.59k)
  • Dr. Alessandra Cesano, Chief Medical Officer
  • Mr. David S. Wood C.M.A., CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer (Age 64)
  • Chandtip Chandhasin, Exec.
  • Erica Osbourne, Exec.
  • Erin Rudsinski, Exec.
  • Leah Dimascio, Exec.
  • Loleta Harris, Exec.
  • Neil Thapar, Exec.

Who are some of ESSA Pharma's key competitors?

What other stocks do shareholders of ESSA Pharma own?

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BVF Inc. IL (8.61%), Vivo Capital LLC (6.12%), Bellevue Group AG (5.41%), Janus Henderson Group PLC (4.49%), Boxer Capital LLC (2.03%) and Morgan Stanley (1.70%).
View institutional ownership trends for ESSA Pharma

Which institutional investors are selling ESSA Pharma stock?

EPIX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Omega Fund Management LLC, Silverarc Capital Management LLC, and Millennium Management LLC.
View insider buying and selling activity for ESSA Pharma
or view top insider-selling stocks.

Which institutional investors are buying ESSA Pharma stock?

EPIX stock was bought by a variety of institutional investors in the last quarter, including Bellevue Group AG, Janus Henderson Group PLC, Boxer Capital LLC, Rock Springs Capital Management LP, Sectoral Asset Management Inc, Frazier Management LLC, Acuta Capital Partners LLC, and Ally Bridge Group NY LLC.
View insider buying and selling activity for ESSA Pharma
or or view top insider-buying stocks.

How do I buy shares of ESSA Pharma?

Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ESSA Pharma's stock price today?

One share of EPIX stock can currently be purchased for approximately $27.29.

How much money does ESSA Pharma make?

ESSA Pharma has a market capitalization of $921.86 million. The company earns $-23,440,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does ESSA Pharma have?

ESSA Pharma employs 25 workers across the globe.

What is ESSA Pharma's official website?

The official website for ESSA Pharma is

Where are ESSA Pharma's headquarters?

ESSA Pharma is headquartered at 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 778-331-0962 or via email at [email protected]

This page was last updated on 6/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.